Erin Ann Bohula May, M.D., D.Phil.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Simvastatin | 10 | 2019 | 350 | 3.450 |
Why?
|
| Anticholesteremic Agents | 12 | 2020 | 966 | 2.740 |
Why?
|
| Coronary Care Units | 5 | 2020 | 208 | 2.370 |
Why?
|
| Acute Coronary Syndrome | 14 | 2019 | 2202 | 2.320 |
Why?
|
| Benzazepines | 5 | 2019 | 333 | 2.080 |
Why?
|
| Shock, Cardiogenic | 5 | 2020 | 576 | 1.710 |
Why?
|
| Cholesterol, LDL | 9 | 2020 | 2333 | 1.220 |
Why?
|
| Myocardial Infarction | 12 | 2020 | 11304 | 1.200 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 9 | 2018 | 3085 | 1.180 |
Why?
|
| Anti-Obesity Agents | 2 | 2018 | 202 | 1.130 |
Why?
|
| Intra-Aortic Balloon Pumping | 3 | 2020 | 217 | 1.060 |
Why?
|
| Overweight | 4 | 2019 | 2212 | 1.040 |
Why?
|
| Hypolipidemic Agents | 2 | 2019 | 613 | 1.020 |
Why?
|
| Lactones | 3 | 2016 | 345 | 0.990 |
Why?
|
| Serotonin 5-HT2 Receptor Agonists | 2 | 2019 | 38 | 0.880 |
Why?
|
| Secondary Prevention | 6 | 2017 | 1509 | 0.860 |
Why?
|
| Appetite Depressants | 2 | 2019 | 116 | 0.860 |
Why?
|
| Heart-Assist Devices | 4 | 2020 | 1227 | 0.820 |
Why?
|
| C-Reactive Protein | 3 | 2018 | 3691 | 0.800 |
Why?
|
| Double-Blind Method | 18 | 2020 | 12008 | 0.770 |
Why?
|
| Pyridines | 4 | 2016 | 2875 | 0.770 |
Why?
|
| Cardiovascular Diseases | 10 | 2020 | 14054 | 0.650 |
Why?
|
| Obesity | 5 | 2019 | 12008 | 0.620 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2018 | 186 | 0.610 |
Why?
|
| Extracorporeal Membrane Oxygenation | 4 | 2020 | 1232 | 0.580 |
Why?
|
| Atherosclerosis | 4 | 2020 | 3183 | 0.560 |
Why?
|
| Stroke | 6 | 2020 | 9239 | 0.530 |
Why?
|
| Receptor, IGF Type 1 | 4 | 2006 | 398 | 0.520 |
Why?
|
| Clinical Chemistry Tests | 1 | 2013 | 64 | 0.500 |
Why?
|
| Dyslipidemias | 2 | 2018 | 841 | 0.500 |
Why?
|
| Weight Loss | 4 | 2019 | 2463 | 0.490 |
Why?
|
| Hemodynamics | 3 | 2020 | 4199 | 0.460 |
Why?
|
| Heart Diseases | 3 | 2019 | 2751 | 0.450 |
Why?
|
| Hypoglycemia | 1 | 2018 | 805 | 0.440 |
Why?
|
| Registries | 5 | 2020 | 8019 | 0.430 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2015 | 335 | 0.430 |
Why?
|
| Disease Management | 3 | 2020 | 2539 | 0.430 |
Why?
|
| Risk Assessment | 10 | 2019 | 23519 | 0.400 |
Why?
|
| Biological Assay | 1 | 2013 | 668 | 0.390 |
Why?
|
| Ischemic Attack, Transient | 1 | 2015 | 905 | 0.390 |
Why?
|
| Critical Illness | 2 | 2019 | 2471 | 0.380 |
Why?
|
| Aged | 29 | 2020 | 162592 | 0.350 |
Why?
|
| Troponin T | 1 | 2013 | 737 | 0.350 |
Why?
|
| Thiazoles | 1 | 2016 | 1551 | 0.350 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2018 | 10791 | 0.340 |
Why?
|
| Lipids | 1 | 2019 | 3233 | 0.330 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 1808 | 0.330 |
Why?
|
| North America | 3 | 2020 | 1197 | 0.330 |
Why?
|
| Middle Aged | 31 | 2020 | 215428 | 0.330 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3163 | 0.320 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3276 | 0.320 |
Why?
|
| Risk Factors | 17 | 2020 | 70264 | 0.310 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 2728 | 0.290 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 2094 | 0.290 |
Why?
|
| Treatment Outcome | 17 | 2020 | 61963 | 0.290 |
Why?
|
| Kidney | 2 | 2019 | 6872 | 0.260 |
Why?
|
| Drug Therapy, Combination | 6 | 2019 | 6583 | 0.260 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 2987 | 0.260 |
Why?
|
| Male | 32 | 2020 | 351848 | 0.260 |
Why?
|
| Hyphae | 1 | 2003 | 56 | 0.250 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2016 | 2970 | 0.250 |
Why?
|
| Female | 33 | 2020 | 377269 | 0.240 |
Why?
|
| Survival Rate | 7 | 2020 | 13363 | 0.240 |
Why?
|
| Vacuoles | 1 | 2003 | 233 | 0.230 |
Why?
|
| Humans | 46 | 2020 | 709431 | 0.230 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2013 | 1469 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 9857 | 0.220 |
Why?
|
| Aortic Valve Stenosis | 1 | 2013 | 1823 | 0.200 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2020 | 67 | 0.200 |
Why?
|
| Creatinine | 2 | 2016 | 1895 | 0.200 |
Why?
|
| Candida albicans | 1 | 2003 | 370 | 0.200 |
Why?
|
| Hospitalization | 1 | 2019 | 9632 | 0.190 |
Why?
|
| Recurrence | 3 | 2017 | 8279 | 0.190 |
Why?
|
| Comprehensive Health Care | 1 | 2019 | 131 | 0.180 |
Why?
|
| Chloroquine | 1 | 2020 | 286 | 0.180 |
Why?
|
| Appetite Regulation | 1 | 2019 | 86 | 0.180 |
Why?
|
| Critical Care | 3 | 2020 | 2490 | 0.180 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2020 | 116 | 0.180 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2019 | 149 | 0.170 |
Why?
|
| Hospital Mortality | 4 | 2020 | 5117 | 0.170 |
Why?
|
| Time Factors | 7 | 2020 | 41295 | 0.170 |
Why?
|
| Inflammation | 1 | 2018 | 9948 | 0.170 |
Why?
|
| Cardiology Service, Hospital | 1 | 2020 | 250 | 0.170 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 324 | 0.170 |
Why?
|
| Canada | 2 | 2020 | 1933 | 0.170 |
Why?
|
| Alanine | 1 | 2020 | 610 | 0.160 |
Why?
|
| Renal Replacement Therapy | 1 | 2020 | 255 | 0.160 |
Why?
|
| RNA, Small Interfering | 2 | 2006 | 3660 | 0.160 |
Why?
|
| Plasma | 1 | 2020 | 565 | 0.150 |
Why?
|
| Organizational Innovation | 1 | 2020 | 572 | 0.150 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 39394 | 0.150 |
Why?
|
| Adamantane | 1 | 2017 | 178 | 0.150 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 388 | 0.150 |
Why?
|
| Pandemics | 3 | 2020 | 6922 | 0.150 |
Why?
|
| Virus Internalization | 1 | 2020 | 466 | 0.150 |
Why?
|
| Metabolic Clearance Rate | 1 | 2016 | 406 | 0.150 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 12442 | 0.140 |
Why?
|
| Dipeptides | 1 | 2017 | 413 | 0.140 |
Why?
|
| Receptors, Thrombin | 1 | 2015 | 139 | 0.140 |
Why?
|
| Calibration | 1 | 2017 | 804 | 0.140 |
Why?
|
| Receptor, PAR-1 | 1 | 2015 | 115 | 0.140 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2017 | 234 | 0.140 |
Why?
|
| Patient Admission | 2 | 2019 | 1405 | 0.130 |
Why?
|
| Cell Cycle | 1 | 2003 | 3032 | 0.130 |
Why?
|
| Prospective Studies | 5 | 2019 | 50734 | 0.130 |
Why?
|
| Endpoint Determination | 1 | 2017 | 631 | 0.130 |
Why?
|
| Hemorrhage | 2 | 2016 | 3208 | 0.130 |
Why?
|
| Incidence | 5 | 2020 | 20587 | 0.130 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2018 | 572 | 0.130 |
Why?
|
| Azetidines | 1 | 2015 | 148 | 0.130 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 706 | 0.130 |
Why?
|
| Prediabetic State | 1 | 2018 | 468 | 0.120 |
Why?
|
| Antimalarials | 1 | 2020 | 854 | 0.120 |
Why?
|
| Cerebral Revascularization | 1 | 2015 | 227 | 0.120 |
Why?
|
| Thrombophilia | 1 | 2016 | 320 | 0.120 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 986 | 0.120 |
Why?
|
| Hypercholesterolemia | 1 | 2020 | 1163 | 0.120 |
Why?
|
| Limit of Detection | 1 | 2013 | 249 | 0.120 |
Why?
|
| Remission Induction | 1 | 2018 | 2414 | 0.120 |
Why?
|
| Placebo Effect | 1 | 2017 | 603 | 0.120 |
Why?
|
| Morbidity | 1 | 2018 | 1694 | 0.120 |
Why?
|
| Tissue and Organ Procurement | 1 | 2020 | 848 | 0.110 |
Why?
|
| Electrocardiography | 2 | 2016 | 6390 | 0.110 |
Why?
|
| Troponin I | 1 | 2016 | 627 | 0.110 |
Why?
|
| Neurology | 1 | 2019 | 731 | 0.110 |
Why?
|
| Myocardial Revascularization | 1 | 2015 | 843 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6830 | 0.100 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 954 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 2098 | 0.100 |
Why?
|
| Tissue Donors | 1 | 2020 | 2148 | 0.100 |
Why?
|
| Internationality | 1 | 2015 | 1001 | 0.090 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 2015 | 0.090 |
Why?
|
| Peripheral Arterial Disease | 1 | 2020 | 1193 | 0.090 |
Why?
|
| Atrial Fibrillation | 2 | 2017 | 4381 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2015 | 936 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2019 | 2956 | 0.090 |
Why?
|
| Cardiology | 1 | 2019 | 1621 | 0.090 |
Why?
|
| Warfarin | 1 | 2016 | 1437 | 0.080 |
Why?
|
| Kidney Diseases | 1 | 2019 | 2131 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2018 | 1484 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2020 | 2744 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 1887 | 0.080 |
Why?
|
| Comorbidity | 3 | 2018 | 10621 | 0.080 |
Why?
|
| Body Weight | 1 | 2018 | 4720 | 0.080 |
Why?
|
| RNA, Messenger | 1 | 2003 | 13351 | 0.080 |
Why?
|
| Heart Transplantation | 1 | 2020 | 3073 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 11384 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2013 | 1592 | 0.080 |
Why?
|
| Life Style | 1 | 2017 | 3711 | 0.070 |
Why?
|
| Prosthesis Design | 1 | 2013 | 2135 | 0.070 |
Why?
|
| Echocardiography | 1 | 2018 | 5123 | 0.070 |
Why?
|
| Disease Progression | 2 | 2019 | 13298 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2013 | 2863 | 0.070 |
Why?
|
| Heart Valve Prosthesis | 1 | 2013 | 1488 | 0.060 |
Why?
|
| Prognosis | 3 | 2019 | 29148 | 0.060 |
Why?
|
| Risk | 1 | 2016 | 9813 | 0.060 |
Why?
|
| United States | 4 | 2020 | 67177 | 0.060 |
Why?
|
| Forecasting | 1 | 2013 | 2957 | 0.060 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2003 | 119 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 58752 | 0.060 |
Why?
|
| RNA, Antisense | 1 | 2003 | 144 | 0.060 |
Why?
|
| Sex Factors | 2 | 2017 | 10744 | 0.060 |
Why?
|
| Patient Discharge | 1 | 2015 | 2963 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 4747 | 0.060 |
Why?
|
| Research Design | 1 | 2018 | 5860 | 0.060 |
Why?
|
| Hydroxyurea | 1 | 2003 | 291 | 0.060 |
Why?
|
| Nitrogen | 1 | 2003 | 352 | 0.060 |
Why?
|
| G1 Phase | 1 | 2003 | 422 | 0.060 |
Why?
|
| Serum | 1 | 2003 | 220 | 0.060 |
Why?
|
| Age Factors | 1 | 2019 | 18954 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2015 | 10603 | 0.050 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2003 | 434 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2006 | 13763 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 16161 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2016 | 4250 | 0.050 |
Why?
|
| Culture Media | 1 | 2003 | 966 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 2006 | 6659 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 5231 | 0.050 |
Why?
|
| Patient Selection | 1 | 2013 | 4322 | 0.050 |
Why?
|
| Gene Silencing | 2 | 2006 | 1638 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2017 | 12426 | 0.050 |
Why?
|
| Diet | 1 | 2017 | 7505 | 0.050 |
Why?
|
| Nucleic Acid Conformation | 1 | 2003 | 1031 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2001 | 514 | 0.040 |
Why?
|
| Civil Defense | 1 | 2020 | 111 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 6137 | 0.040 |
Why?
|
| Organizational Objectives | 1 | 2020 | 436 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2001 | 580 | 0.040 |
Why?
|
| Cattle | 1 | 2003 | 4024 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 15316 | 0.040 |
Why?
|
| Shock | 1 | 2018 | 322 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2006 | 1936 | 0.040 |
Why?
|
| Diet, Reducing | 1 | 2019 | 471 | 0.030 |
Why?
|
| Cell Division | 1 | 2003 | 4787 | 0.030 |
Why?
|
| Neoplasms | 1 | 2003 | 20421 | 0.030 |
Why?
|
| Aorta | 1 | 2003 | 2114 | 0.030 |
Why?
|
| Kinetics | 1 | 2003 | 6893 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 39650 | 0.030 |
Why?
|
| RNA Interference | 1 | 2003 | 3027 | 0.030 |
Why?
|
| Catheterization | 1 | 2019 | 1467 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2001 | 3125 | 0.030 |
Why?
|
| Adult | 2 | 2018 | 212298 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2019 | 1560 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 1123 | 0.030 |
Why?
|
| Consensus | 1 | 2019 | 2668 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2003 | 3398 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2018 | 1142 | 0.020 |
Why?
|
| Heart Arrest | 1 | 2018 | 1346 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2018 | 2142 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2001 | 3884 | 0.020 |
Why?
|
| Melanoma | 1 | 2006 | 5503 | 0.020 |
Why?
|
| Triglycerides | 1 | 2015 | 2559 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2003 | 20303 | 0.020 |
Why?
|
| Coronary Artery Bypass | 1 | 2016 | 2371 | 0.020 |
Why?
|
| Transfection | 2 | 2006 | 6193 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2018 | 3422 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2001 | 8733 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 660 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2018 | 3712 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2019 | 8512 | 0.010 |
Why?
|
| Melanocytes | 1 | 2006 | 532 | 0.010 |
Why?
|
| Animals | 3 | 2003 | 170647 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2001 | 60 | 0.010 |
Why?
|
| Ataxia Telangiectasia | 1 | 2001 | 94 | 0.010 |
Why?
|
| Point Mutation | 1 | 2006 | 1669 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 22944 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2006 | 1665 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2001 | 2190 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 2595 | 0.010 |
Why?
|
| Heart Failure | 1 | 2019 | 9901 | 0.010 |
Why?
|
| Cell Survival | 1 | 2006 | 6184 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2001 | 3904 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2001 | 2067 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2020 | 71151 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2006 | 5227 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2001 | 8737 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 5349 | 0.010 |
Why?
|
| Apoptosis | 1 | 2001 | 10133 | 0.000 |
Why?
|
| Phenotype | 1 | 2001 | 16295 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 2001 | 23044 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2006 | 23985 | 0.000 |
Why?
|
| Mice | 1 | 2001 | 80950 | 0.000 |
Why?
|